Shots:Monica spoke about the data from the NOVA P-IIIb study evaluating the efficacy of its lead candidate in Multiple Sclerosis(MS)Monica also talked about the clinical trial results and formulation of the advanced product in MSThe interview gives a view of Biogen’s developing molecules in the pipeline for MSSmriti: Can you share with…
In an interview with PharmaShots, Monica Mann, Vice President, Medical Affairs for Global MS and Pipeline at Biogen shared her views on the data of Tysabri, Vumerity & highlights of new digital health research to predict multiple sclerosis disease progressionShots:Monica spoke about detailed results of the new real-world & clinical data on the long-term use of Tysabri & real-world analyses…
In an interview with PharmaShots, Monica Mann, Head of Global Medical, Multiple Sclerosis at Biogen shares her views on the Plegridy and how it works on MS patients. She also shed light on the approval of the therapy in the US and EU.Shots:The approval of Plegridy (IM) by the EC and the US FDA is based on…

